JAC Advance Access originally published online on July 2, 2007
Journal of Antimicrobial Chemotherapy 2007 60(3):461-463; doi:10.1093/jac/dkm241
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leading articles |
Improved survival in HIV-infected persons: consequences and perspectives
1 Department of Clinical Epidemiology, Århus University Hospital, DK-8000 Århus C, Denmark 2 The Danish HIV Cohort Study, Copenhagen University Hospital Rigshospitalet, DK-2100 Copenhagen, Denmark 3 Department of Infectious Diseases, Odense University Hospital and Clinical Institute, University of Southern Denmark, DK-5000 Odense, Denmark 4 Department of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, DK-2100 Copenhagen, Denmark
* Corresponding author. Tel: +45-894-24800; Fax: +45-894-24801; E-mail: nl{at}dce.au.dk
A human immunodeficiency virus (HIV) patient in 2007 has the option to commence an antiretroviral regimen that is extremely efficacious in suppressing the virus and has few side effects. In a recent study, we estimated the median remaining lifetime of a newly diagnosed 25-year-old HIV-infected individual to be 39 years. The prospect of a near-normal life expectancy has implications for the HIV-infected persons as well as for the handling of the disease in the healthcare system. The patients can now on a long-term perspective plan their professional career, join a pension plan and start a family. Further, they may expect to be treated equally with other members of society with respect to access to mortgage, health insurance and life insurance. As the infected population ages, more patients will contract age-related diseases, and the disease burden on some individuals may even come to be dominated by non-HIV-related conditions that may have a worse prognosis and therefore become more important than HIV-related conditions. Despite the improvements in antiretroviral therapy, there is still an excess mortality among HIV patients, which appears to be only partially attributable to immunodeficiency, with lifestyle factors potentially playing a pronounced role. Consequently, an effort to further increase survival must target risk factors for both HIV-related and -unrelated mortality. The continuation of the positive trend may be achieved by increased HIV testing, earlier initiation of antiretroviral therapy, improved drug adherence, prevention and treatment of HIV-unrelated co-morbidity and collaboration with other medical specialists to treat an ageing co-morbidity-acquiring HIV population.
Keywords: prognosis , treatment strategies , co-morbidity , mortality
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Obel, F. N Engsig, L. D Rasmussen, M. V Larsen, L. H Omland, and H. T Sorensen Cohort Profile: The Danish HIV Cohort Study Int. J. Epidemiol., October 1, 2009; 38(5): 1202 - 1206. [Full Text] [PDF]
|
|